Market Research Report
Global Neurodegenerative Diseases Therapeutics Market 2018 -2022
|Published by||TechNavio (Infiniti Research Ltd.)||Product code||762875|
|Published||Content info||113 Pages
Delivery time: 1-2 business days
|Global Neurodegenerative Diseases Therapeutics Market 2018 -2022|
|Published: December 17, 2018||Content info: 113 Pages||
Increase in aging population to drive growth in the market. The aging population has been increasing globally with declining fertility and increasing longevity. Medicine has prolonged the morbidity phase, which has, in turn increased the risk of developing neurological disorders such as Alzheimer's and Parkinson's disease. Technavio's analysts have predicted that the neurodegenerative diseases therapeutics market will register a CAGR of almost 8% by 2022.
The development of advanced diagnostic modalities to identify disease manifestation at its earliest stages facilitates early treatment decisions, thereby easing disease burden. Neuroimaging is one of the methods for the early diagnosis of neurodegenerative diseases.
There has been a continuous development of drugs for the treatment of neurodegenerative diseases. However, there is reportedly a high failure rate of neurodegenerative drugs in clinical trials.
For the detailed list of factors that will drive and challenge the growth of the neurodegenerative diseases therapeutics market during the 2018-2022, view our report.
The market appears to be fragmented and with the presence of several companies including Novartis and Teva Pharmaceutical the competitive environment is quite intense. Factors such as the increase in aging population and the availability of highly sensitive diagnostic modalities, will provide considerable growth opportunities to neurodegenerative diseases therapeutics manufactures. ALLERGAN, Biogen, Novartis, and Teva Pharmaceutical are some of the major companies covered in this report.